Table 1.
TAN Positivity According to Baseline Patient Characteristics
| Variable | n | TAN - (n=77), n(%) | TAN + (n=28), n(%) | p |
|---|---|---|---|---|
| Age (median) | - | 56 (30-88) | 51 (32-80) | 0.12 |
| Menopausal status | ||||
| Premenopausal | 39 | 28 (36%) | 11 (39%) | |
| Posmenopausal | 66 | 49 (64%) | 17 (61%) | 0.822 |
| Clinical T stage | ||||
| 1 | 32 | 26 (34%) | 6 (21%) | |
| 2 | 51 | 37 (48%) | 14 (50%) | |
| 3 | 15 | 10 (13%) | 5 (18%) | |
| 4 | 7 | 4 (5%) | 3 (11%) | 0.478 |
| Clinical N stage | ||||
| 0 | 55 | 42 (54%) | 13 (46%) | |
| 1 | 42 | 32 (42%) | 10 (36%) | |
| 2 | 8 | 3 (4%) | 5 (18%) | 0.077 |
| Histology | ||||
| Lobular | 12 | 12 (15%) | 0 (0%) | |
| Grade 1 Ductal | 19 | 19 (25%) | 0 (0%) | |
| Grade 2 Ductal | 49 | 37 (48%) | 12 (43%) | |
| Grade 3 Ductal | 25 | 9 (12%) | 16 (57%) | <0.001 |
| Hormone Receptor status (HR) | ||||
| Negative | 24 | 5 (6%) | 19 (68%) | |
| Positive | 81 | 72 (94%) | 9 (32%) | <0.001 |
| HER2 status | ||||
| Negative | 90 | 70 (91%) | 20 (71%) | |
| Positive | 15 | 7 (9%) | 8 (29%) | 0.023 |
| Tumor Subtype | ||||
| HR+, HER2-ve | 72 | 68 (88%) | 4 (14%) | |
| HER2+ | 15 | 7 (9%) | 8 (29%) | |
| Triple negative | 18 | 2 (3%) | 16 (57%) | <0.001 |